NASDAQ:OCGN Ocugen (OCGN) Stock Price, News & Analysis $1.34 -0.01 (-0.37%) As of 02:03 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ocugen Stock (NASDAQ:OCGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ocugen alerts:Sign Up Key Stats Today's Range$1.33▼$1.3850-Day Range$1.30▼$2.4852-Week Range$0.80▼$2.73Volume2.19 million shsAverage Volume7.59 million shsMarket Capitalization$455.31 millionP/E RatioN/ADividend YieldN/APrice Target$9.75Consensus RatingModerate Buy Company Overview Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline. In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders. Lead candidates include OCU400 for retinitis pigmentosa and OCU410 for wet age-related macular degeneration, each engineered to deliver functional genetic material to retinal cells. The company’s approach is rooted in adeno-associated viral (AAV) vector technology, which has the potential to enable single-administration treatments and durable therapeutic benefits for patients facing progressive vision loss. On the vaccine front, Ocugen entered into a collaboration with India-based Bharat Biotech in mid-2020 to co-develop and commercialize the COVID-19 vaccine Covaxin in the United States and Canada. This partnership illustrates Ocugen’s ability to partner with established developers to bring critical vaccine candidates into North American regulatory pathways. The company is also exploring additional vaccine opportunities that may leverage its manufacturing and distribution networks. Founded in 2014, Ocugen is led by President and Chief Executive Officer Dr. Shankar Musunuri, who co-founded the company with the goal of addressing conditions with limited or no treatment options. Under his leadership and that of an experienced management team, Ocugen continues to advance its pipeline through clinical trials and regulatory interactions, with a mission to deliver innovative therapies for patients worldwide.AI Generated. May Contain Errors. Read More Ocugen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreOCGN MarketRank™: Ocugen scored higher than 29% of companies evaluated by MarketBeat, and ranked 708th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingOcugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialOcugen has a consensus price target of $9.75, representing about 619.6% upside from its current price of $1.36.Amount of Analyst CoverageOcugen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ocugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocugen are expected to decrease in the coming year, from ($0.22) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcugen has a P/B Ratio of 67.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ocugen's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.43% of the float of Ocugen has been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 11.56, which indicates bearish sentiment.Change versus previous monthShort interest in Ocugen has recently increased by 2.63%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Ocugen this week, compared to 5 articles on an average week.Search InterestOnly 12 people have searched for OCGN on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have not sold or bought any company stock.Percentage Held by Insiders3.95% of the stock of Ocugen is held by insiders.Percentage Held by Institutions10.27% of the stock of Ocugen is held by institutions.Read more about Ocugen's insider trading history. Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCGN Stock News HeadlinesOcugen (NASDAQ:OCGN) Upgraded at Wall Street ZenMay 16, 2026 | americanbankingnews.comOcugen Announces Interim Chief Medical Officer Appointment TransitionMay 14, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.May 22 at 1:00 AM | Porter & Company (Ad)Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | finance.yahoo.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | globenewswire.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | finance.yahoo.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | finance.yahoo.comSee More Headlines OCGN Stock Analysis - Frequently Asked Questions How have OCGN shares performed this year? Ocugen's stock was trading at $1.35 at the start of the year. Since then, OCGN stock has increased by 0.4% and is now trading at $1.3550. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The firm earned $1.53 million during the quarter, compared to the consensus estimate of $0.42 million. Ocugen had a negative net margin of 1,192.18% and a negative trailing twelve-month return on equity of 127,987.80%. Read the conference call transcript. When did Ocugen IPO? Ocugen (OCGN) raised $83 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 5,909,091 shares at $13.00-$15.00 per share. Who are Ocugen's major shareholders? Ocugen's top institutional shareholders include Bank of America Corp DE (0.35%), Procyon Advisors LLC (0.13%), NewEdge Advisors LLC (0.05%) and OMERS ADMINISTRATION Corp (0.03%). Insiders that own company stock include Junge Zhang and Prabhavathi Fernandes. View institutional ownership trends. How do I buy shares of Ocugen? Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocugen investors own include Zomedica (ZOM), American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and The RMR Group (RMR). Company Calendar Last Earnings5/05/2026Today5/22/2026Stifel 2026 Virtual Ophthalmology Forum5/26/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, OCGN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCGN CIK1372299 Webocugen.com Phone(484) 328-4701Fax781-547-4452Employees80Year Founded2013Price Target and Rating Average Price Target for Ocugen$9.75 High Price Target$12.00 Low Price Target$7.00 Potential Upside/Downside+614.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.85 million Net Margins-1,192.18% Pretax Margin-1,605.22% Return on Equity-127,987.80% Return on Assets-135.48% Debt Debt-to-Equity Ratio4.17 Current Ratio1.86 Quick Ratio1.86 Sales & Book Value Annual Sales$4.41 million Price / Sales104.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book68.25Miscellaneous Outstanding Shares338,520,000Free Float325,150,000Market Cap$462.08 million OptionableOptionable Beta2.30 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:OCGN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
